Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

Hims & Hers Health Inc. won’t back down from selling cheap weight-loss shots, its chief executive officer said one day after Novo Nordisk A/S abruptly ended its distribution partnership. “We’re upset ...

The Law Offices of Frank R. Cruz announces an investigation of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) on behalf of investors concerning the Company's possible violations of ...

Novo Nordisk has cut ties with Hims & Hers Health, alleging that the latter company has engaged in deceptive marketing ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated ...

What if I purchased Hims & Hers securities? If you incurred significant losses and want to determine if you are eligible to participate in the potential class action or to seek a recovery of your ...

The CEO of the world's biggest retail trading platform says that everyday investors are doubling down on their bets despite tensions in the Middle East and other geopolitical uncertainty.

Hims & Hers fell by 34.63 percent on Monday to close at $41.98 apiece after Novo Nordisk terminated its marketing partnership ...

Novo Nordisk has terminated its partnership with telehealth company Hims & Hers Health, accusing it of deceptively marketing ...

Find insight on Novo Nordisk and more in the latest Market Talks covering the Health Care sector..